Stoke Therapeutics, Inc. (STOK) shares soared 9.4% in the last trading session to close at $12.60. The move was backed by solid volume with far more shares changing hands than in a normal session.

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency in patients with developmental and epileptic encephalopathies while ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB ...

Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin ...

for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene. Zorevunersen is being developed as potentially BEDFORD ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

After hours: January 31 at 4:31:02 PM EST Loading Chart for STOK ...

Dravet Syndrome Market Outlook 2025-2035: The 7 major Dravet syndrome market reached a value of USD 402.4 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 854.0 Million by ...

The number of Marylanders confirmed dead in an aviation crash near Ronald Reagan Washington National Airport that shook the ...

Learn about cystic fibrosis, a genetic disorder that affects the lungs, pancreas, and other organs, and how to treat and live with this chronic disease. 12 min read What Is Cystic Fibrosis? Cystic ...